<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-document PUBLIC "-//MXW//DTD patent-document XML//EN" "http://www.ir-facility.org/dtds/patents/v1.4/patent-document.dtd">
<patent-document ucid="EP-1000006-B1" country="EP" doc-number="1000006" kind="B1" lang="EN" family-id="25415952" status="new" date-produced="20100220" date="20030122">
  <bibliographic-data>
    <publication-reference ucid="EP-1000006-B1" status="new" fvid="22846476">
      <document-id status="new" format="original">
        <country status="new">EP</country>
        <doc-number>1000006</doc-number>
        <kind>B1</kind>
        <date>20030122</date>
        <lang>EN</lang>
      </document-id>
    </publication-reference>
    <application-reference load-source="docdb" ucid="EP-98937268-A" status="new" mxw-id="PAPP18318424" is-representative="NO">
      <document-id status="new" format="epo">
        <country status="new">EP</country>
        <doc-number>98937268</doc-number>
        <kind>A</kind>
        <date>19980729</date>
        <lang>EN</lang>
      </document-id>
    </application-reference>
    <priority-claims status="new">
      <priority-claim ucid="US-9815763-W" status="new" mxw-id="PPC22673501">
        <document-id status="new" format="epo">
          <country status="new">US</country>
          <doc-number>9815763</doc-number>
          <kind>W</kind>
          <date>19980729</date>
        </document-id>
      </priority-claim>
      <priority-claim ucid="US-90250897-A" status="new" mxw-id="PPC22679955">
        <document-id status="new" format="epo">
          <country status="new">US</country>
          <doc-number>90250897</doc-number>
          <kind>A</kind>
          <date>19970729</date>
        </document-id>
      </priority-claim>
      <priority-claim status="new" mxw-id="PPC92187371">
        <document-id status="new" format="original">
          <country status="new">US</country>
          <doc-number>902508</doc-number>
          <date>19970729</date>
        </document-id>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability status="new">
      <intention-to-grant-date>
        <date>20020522</date>
      </intention-to-grant-date>
    </dates-of-public-availability>
    <technical-data status="new">
      <classification-ipc status="new">
        <edition>7</edition>
        <main-classification status="new">C07C  45/50</main-classification>
        <further-classification status="new">C07F   9/145</further-classification>
        <further-classification status="new">C07C 255/17</further-classification>
        <further-classification status="new">C07C  69/716</further-classification>
        <further-classification status="new">C07C  47/02</further-classification>
        <further-classification status="new">C07C  59/147</further-classification>
        <further-classification status="new">C07C  51/373</further-classification>
        <further-classification status="new">C07C  67/347</further-classification>
        <further-classification status="new">C07C  45/80</further-classification>
        <further-classification status="new">C07C 253/30</further-classification>
      </classification-ipc>
      <classifications-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161241884">C07C  69/00        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161243647">C07C  59/00        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161243679">C07C 253/00        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161246927">B01J  31/18        20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161257368">B01J  31/22        20060101AFI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161282209">C07C  45/80        20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161289348">C07C  47/02        20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161296842">C07C  69/716       20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161309614">C07C  51/347       20060101C I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161316496">C07F   9/145       20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161337045">C07C  45/50        20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161341514">C07C 253/30        20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161342126">C07C  67/347       20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161351430">C07C  67/00        20060101C I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161352169">C07C  59/147       20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161364214">C07F   9/00        20060101C I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161368284">C07C 255/00        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161396328">C07C  47/02        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161413191">C07C 255/17        20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161416172">C07C  67/313       20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161417632">C07C  51/373       20060101A I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161419971">C07B  61/00        20060101CLI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161421131">C07B  61/00        20060101ALI20051220RMJP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161435018">C07C  45/00        20060101C I20051008RMEP        </classification-ipcr>
        <classification-ipcr load-source="docdb" status="new" mxw-id="PCL161444399">B01J  31/16        20060101C I20051008RMEP        </classification-ipcr>
      </classifications-ipcr>
      <classification-ecla status="new">
        <classification-symbol scheme="EC" mxw-id="PCL161265768">C07C  51/373+59/147</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL161291786">C07C  67/313+69/716</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL161294159">C07C  45/80</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL161327332">C07C  67/347+69/716</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL161397772">C07F   9/145+J</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL161430837">C07C  45/50</classification-symbol>
        <classification-symbol scheme="ICO" mxw-id="PCL622624278">L01J531:82D</classification-symbol>
        <classification-symbol scheme="EC" mxw-id="PCL622624279">B01J  31/18C2</classification-symbol>
        <classification-symbol scheme="ICO" mxw-id="PCL622624280">L01J531:80</classification-symbol>
        <classification-symbol scheme="ICO" mxw-id="PCL622624281">L01J231:32B</classification-symbol>
        <classification-symbol scheme="ICO" mxw-id="PCL622624282">L01J531:02H4</classification-symbol>
      </classification-ecla>
      <invention-title load-source="patent-office" status="new" mxw-id="PT21747848" lang="DE">VERFAHREN ZUR HERSTELLUNG VON RECHTKETTIGEN ALDEHYDEN</invention-title>
      <invention-title load-source="patent-office" status="new" mxw-id="PT21747849" lang="EN">IMPROVED PROCESS OF PREPARATION OF LINEAR ALDEHYDES</invention-title>
      <invention-title load-source="patent-office" status="new" mxw-id="PT21747850" lang="FR">PROCEDE AMELIORE DE PREPARATION D'ALDEHYDES LINEAIRES</invention-title>
    </technical-data>
    <parties>
      <applicants>
        <applicant status="new" sequence="1" mxw-id="PPAR90268677" format="epo">
          <addressbook>
            <name>DSM NV</name>
            <address>
              <country status="new">NL</country>
            </address>
          </addressbook>
        </applicant>
        <applicant status="new" sequence="2" mxw-id="PPAR90232064" format="epo">
          <addressbook>
            <name>DU PONT</name>
            <address>
              <country status="new">US</country>
            </address>
          </addressbook>
        </applicant>
        <applicant status="new" sequence="1" mxw-id="PPAR90246277" format="intermediate">
          <addressbook>
            <name>DSM N.V.</name>
          </addressbook>
        </applicant>
        <applicant status="new" sequence="2" mxw-id="PPAR90203382" format="intermediate">
          <addressbook>
            <name>E.I. DU PONT DE NEMOURS AND COMPANY</name>
          </addressbook>
        </applicant>
      </applicants>
      <inventors>
        <inventor status="new" sequence="1" mxw-id="PPAR90241529" format="epo">
          <addressbook>
            <name>BUNEL EMILIO ENRIQUE</name>
            <address>
              <country status="new">US</country>
            </address>
          </addressbook>
        </inventor>
        <inventor status="new" sequence="1" mxw-id="PPAR90254934" format="intermediate">
          <addressbook>
            <name>BUNEL, EMILIO, ENRIQUE</name>
          </addressbook>
        </inventor>
        <inventor status="new" sequence="1" mxw-id="PPAR276888168" format="original">
          <addressbook>
            <last-name>BUNEL, EMILIO, ENRIQUE</last-name>
            <address>
              <street>521 Andover Road</street>
              <city>Wilmington, DE 19803</city>
              <country status="new">US</country>
            </address>
          </addressbook>
        </inventor>
      </inventors>
      <assignees>
        <assignee status="new" sequence="1" mxw-id="PPAR276892844" format="original">
          <addressbook>
            <last-name>DSM N.V.</last-name>
            <address>
              <street>Het Overloon 1</street>
              <city>6411 TE Heerlen</city>
              <country status="new">NL</country>
            </address>
          </addressbook>
        </assignee>
        <assignee status="new" sequence="2" mxw-id="PPAR276893171" format="original">
          <addressbook>
            <last-name>E.I. DU PONT DE NEMOURS AND COMPANY</last-name>
            <address>
              <street>1007 Market Street</street>
              <city>Wilmington Delaware 19898</city>
              <country status="new">US</country>
            </address>
          </addressbook>
        </assignee>
      </assignees>
      <agents>
        <agent status="new" sequence="1" mxw-id="PPAR276884527" format="original">
          <addressbook>
            <last-name>Jones, Alan John</last-name>
            <address>
              <street>CARPMAELS &amp;amp; RANSFORD 43 Bloomsbury Square</street>
              <city>London, WC1A 2RA</city>
              <country status="new">GB</country>
            </address>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <international-convention-data>
      <pct-or-regional-filing-data ucid="US-9815763-W" status="new">
        <document-id status="new" format="original">
          <country status="new">US</country>
          <doc-number>9815763</doc-number>
          <kind>W</kind>
          <lang>EN</lang>
        </document-id>
      </pct-or-regional-filing-data>
      <pct-or-regional-publishing-data ucid="WO-1999006345-A1" status="new">
        <document-id status="new" format="original">
          <country status="new">WO</country>
          <doc-number>1999006345</doc-number>
          <kind>A1</kind>
          <date>19990211</date>
          <lang>EN</lang>
        </document-id>
      </pct-or-regional-publishing-data>
      <designated-states>
        <ep-contracting-states>
          <country status="new" mxw-id="DS16840158">BE</country>
          <country status="new" mxw-id="DS16840159">DE</country>
          <country status="new" mxw-id="DS16840160">FR</country>
          <country status="new" mxw-id="DS16840161">GB</country>
          <country status="new" mxw-id="DS16840162">IT</country>
          <country status="new" mxw-id="DS16840163">NL</country>
        </ep-contracting-states>
      </designated-states>
    </international-convention-data>
    <office-specific-data>
      <eptags>
        <ep-no-a-document-published>*</ep-no-a-document-published>
      </eptags>
    </office-specific-data>
  </bibliographic-data>
  <description load-source="patent-office" status="new" mxw-id="PDES17731121" lang="EN">
    <p num="0001">This invention relates to a process for the
preparation of linear aldehydes by hydroformylation of
ethylenically unsaturated organic compounds in the
presence of a catalyst system comprising a Group VIII
metal and an organic phosphite ligand containing phosphorous
having the structure (PR<sub>2</sub>)<sub>n</sub>R' where n is
2, R and R' are organic residues which may be
the same or different and where the R or R' contain at
least one C9 to C40 aliphatic group positioned as a
tail extending away from the primary ligand structure
rendering the ligand lipophilic.</p>
    <heading>
      <b>
        <u style="single">BACKGROUND OF THE INVENTION</u>
      </b>
    </heading>
    <p num="0002">The synthesis of an aldehyde by
hydroformylation is known in the art. A catalyst for
such a process is generally a soluble complex of a
Group VIII transition metal having a phosphorus
containing organic ligand. It is also known that the
selection of the catalyst for the hydroformylation
reaction has an influence on the rate and selectivity
to the product aldehyde(s). Bidentate ligands are
particularly preferred for their combination of
reactivity and selectivity.</p>
    <p num="0003">A number of patents teach structures of
bidentate ligands for hydroformylation reactions that
may be used for the production of aldehydes. U.S. Pat.
No. 5,235,113 teaches a hydroformylation process in
which an organic bidentate phosphite ligand containing
two phosphorus atoms linked with an organic dihydroxyl
bridging group is used with rhodium as a homogeneous
hydroformylation catalyst. </p>
    <p num="0004">Hydroformylation processes involving organic
bidentate ligands containing two trivalent phosphorus
atoms, in which the two phosphorus atoms are linked
with a 2,2'-dihydroxyl-1,1'-binaphthalene bridging
group, have been described in U.S. Pat. Nos. 4,769,498,
4,668,651, 5,113,022, 5,059,710, 5,264,616, and
4,885,401. Additional examples appear in WO-A-9303839
and WO-A-9518089.</p>
    <p num="0005">With respect to the hydroformylation process,
U.S. Pat. No. 4,148,830 teaches the use of high boiling
condensation products of the process as the solvent in
recycling the catalyst system; and U.S. Pat. No.
4,247,486 teaches the use of a gas recycle to control
the liquid level in the reaction and to control the
build-up of high boiling components in the process
stream.</p>
    <p num="0006">These prior patents teach catalyst structures
and improvements in continuous processes for
hydroformylation, but none address the problem of
isolating product, byproduct and catalyst, one from the
other. Yet, in all hydroformylation processes, the
catalyst must be separated from the reaction products.
In the case of hydroformylations such as the present
invention, where the desired reaction product is an
aldehyde, it has proved difficult to separate reaction
products, particularly the higher boiling products and
byproducts, from the catalyst system. The present
invention provides a process by which the reaction
products, including the high boiling products and
byproducts, may be easily separated from the reaction
catalyst system. In the present process the catalyst
system may be readily separated from reaction products
and recycled for use in the process, thus providing
longer active catalyst system productivity.</p>
    <heading>
      <b>
        <u style="single">SUMMARY OF THE INVENTION</u>
      </b>
    </heading>
    <p num="0007">The present invention provides a process for
preparation of a linear aldehyde comprising reacting an
ethylenically unsaturated compound by hydroformylation 
in the presence of a catalyst system composed of a
Group VIII metal and an organic phosphite ligand in a two phase
reaction solvent. The organic phosphite ligand is one containing
phosphorous having the structure (PR<sub>2</sub>)<sub>n</sub>R' where n is
2, R and R' are organic residues
which may be the same or different and where the R or
R' contain at least one C9 to C40 aliphatic group
positioned as a tail extending away from the primary
ligand structure rendering the ligand lipophilic.</p>
    <p num="0008">The hydroformylation reaction
solvent is a two phase mixture of an organic compound
having from 5 to 20 carbon atoms and polar solvent.</p>
    <p num="0009">The present process may be represented as a
series of process steps comprising:
<sl><li>(a) reacting in a reaction solvent to form a
reaction mixture the ethylenically unsaturated compound
in the presence of a catalyst system composed of a
Group VIII metal and organic phosphite ligand containing
phosphorous having the structure (PR<sub>2</sub>)<sub>n</sub>R' where n is
2, R and R' are organic residues
which may be the same or different and where the R or
R' contain at least one C9 to C40 aliphatic group
positioned as a tail extending away from the primary
ligand structure rendering the ligand lipophilic;</li><li>(b) adding a non-polar solvent to the reaction
mixture to form two phases, one a polar phase
predominately formed from the reaction products and one
formed predominately from the non-polar solvent and the
catalyst system such that the reaction products
including the high boiling reaction products of the
hydroformylation remain in the polar phase and the
catalyst system is partitioned substantially into the
non-polar phase; and </li><li>(c) separating the two phases and isolating
the reaction products from the polar phase and the
catalyst from the non-polar phase.</li></sl></p>
    <p num="0010">The preferred ligand a bidentate ligand having
the structure (PR<sub>2</sub>)<sub>2</sub>R' where R and R' are organic
residues and where the R or R' contain at least one C9
to C40 aliphatic group positioned as a tail extending
away from the bridging group(R') or the side arms (R).</p>
    <p num="0011">Volatiles may be removed in the present
process from the reaction mixture of step (a) before
the addition of the non-polar solvent of step (b).
Also in the present process steps (a) and (b) may be
combined and such that the hydroformylation is carried
out in a two phase reaction solvent.</p>
    <p num="0012">The present process may be run as a batch or a
continuous process. In a continuous process the
recovered catalyst is returned to step (a) and the
steps are repeated.</p>
    <p num="0013">The present process also provides an improved
hydroformylation process for preparation of a linear
aldehyde from a reaction mixture containing an
ethylenically unsaturated compound and a catalyst
system composed of a Group VIII metal and a bidentate
organic ligand having two trivalent phosphorous atoms
wherein the ethylenically unsaturated compound also
functions as reaction solvent, the improvement
comprising: forming the catalyst system from a ligand
containing at least one C9 to C40 aliphatic group
positioned on the backbone or side arm ring structures
of the ligand and following hydroformylation of the
ethylenically unsaturated compound adding to the
reaction mixture a two phase solvent mixture consisting
of a polar and a non-polar components so that the
reaction products of the hydroformylation are extracted
into the polar phase of the solvent mixture and the
catalyst system remains substantially in the non-polar
phase of the solvent mixture. </p>
    <p num="0014">Preferred structures for the ligands of the
present invention are Ligands I-IX. As noted below the
basic structure for Ligands I, II and III is the
structure on the left (structure A); the basic
structure for Ligands IV to IX is the structure on the
right (structure B)
<img id="img-00050001" orientation="unknown" wi="145" img-format="tif" img-content="cf" file="00050001.tif" inline="no" he="63"/>
   wherein structures A for Ligands I to III and
structures B for Ligands IV to IX, Ligand I, R<sub>1</sub> is
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub> is H; Ligand II, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub>
is CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; Ligand III is R<sub>1</sub> and R<sub>2</sub> are (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
Ligand IV, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>3</sub> is
H; in Ligand V, R<sub>1</sub> is (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in
Ligand VI, R<sub>1</sub> is CH(CH<sub>3</sub>) (CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in
Ligand VII, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is H and R<sub>3</sub> is
OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; in Ligand VIII, R<sub>1</sub> is
CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) and R<sub>2</sub> and R<sub>3</sub> are H; and in
Ligand IX is CH<sub>2</sub>CH(R<sub>4</sub>)(R<sub>5</sub>) and R<sub>4</sub> and R<sub>5</sub> are the same or
different hydrocarbons having from 6 to 30 carbon
atoms.</p>
    <heading>
      <b>
        <u style="single">DETAILED DESCRIPTION OF THE INVENTION</u>
      </b>
    </heading>
    <p num="0015">The present invention is an improved process
for preparation of a linear aldehyde compound by
hydroformylation in the presence of a catalyst system
comprising a Group VIII metal and organic phosphite ligand
containing phosphorous having the structure (PR<sub>2</sub>)<sub>n</sub>R'
where n is 2, R and R' are organic 
residues which may be the same or different and where
the R or R' contain at least one C9 to C40 aliphatic
group positioned as a tail extending away from the
primary ligand structure rendering the ligand
lipophilic.</p>
    <p num="0016">The preferred ligand of the present invention
is a bidentate ligand having the structure (PR<sub>2</sub>)<sub>2</sub>R'
where R and R' are organic residues and where the R or
R' contain at least one C9 to C40 aliphatic group
positioned as a tail extending away from the bridging
group(R') or the side arms (R) rendering the ligand
lipophilic. The term lipophilic when used to modify
the term ligand means that the ligand, in a two phase
solvent system formed by mixing a polar with a non-polar
solvent, will be substantially distributed in the
non-polar phase.</p>
    <p num="0017">The present process combines a ligand
structure and a two phase process solvent that allows
the easy isolation of reaction products and byproducts
from the catalyst system. The term process solvent as
used herein means a solvent added initially to the
reaction as the reaction solvent or a solvent or a
mixture of solvents added following the reaction that
is used to extract and separate components of the
reaction system. The term extraction means the
preferential partitioning or distribution of a compound
in one of two immiscible liquid phases.</p>
    <p num="0018">A suitable starting material for the present
process is an ethylenically unsaturated compound having
at least one carbon-carbon double bond in the molecule
and preferably from 2 to 20 carbon atoms. Examples of
such ethylenically unsaturated organic compounds are
linear terminal olefinic hydrocarbons, for example,
ethylene, propylene, 1-butene, 1-pentene, 1-hexene, 1-octene,
1-nonene, 1-decene, 1-tetradecene, 1-hexadecene,
1-octadecene, 1-eicosene, and 1-dodecene;
branched terminal olefinic hydrocarbons, for example,
isobutene and 2-methyl-1-butene; linear internal 
olefinic hydrocarbons, for example, cis- and trans-2-butene,
cis- and trans-2-hexene, cis- and trans-2-octene,
cis and trans-3-octene; branched internal
olefinic hydrocarbons, for example, 2,3-dimethyl-2-butene,
2-methyl-2-butene, and 2-methyl-2-pentene;
terminal olefinic hydrocarbon-internal olefinic
hydrocarbon-internal olefinic hydrocarbon mixtures, for
example, octenes prepared by dimerization of butenes;
olefin oligomer isomer mixture from butadiene, dimer to
tetramer of lower butadiene olefins including
propylene, n-butene, isobutene or the like; and
cycloaliphatic olefinic hydrocarbons, for example,
cyclopentene, cyclohexene, 1-methylcyclohexene,
cyclooctene, and limonene.</p>
    <p num="0019">The present invention is especially directed
to hydroformylation process in which a linear aldehyde
compound is prepared starting from internally
unsaturated organic compounds with from 6 to 20 carbon
atoms such as alkyl pentenoates, pentenoic acids or
pentenenitriles.</p>
    <p num="0020">The ethylenically unsaturated organic compound
used in the present process may be substituted with one
or more functional groups containing a heteroatom such
as oxygen, sulfur, nitrogen, or phosphorous. Examples
of these heteroatom-substituted unsaturated organic
compounds include vinyl methyl ether, methyl oleate,
oleyl alcohol, methyl 2-pentenoate, methyl
3-pentenoate, methyl 4-pentenoate, 3-pentenoic acid,
4-pentenoic acid, 3-pentenenitrile, 4-pentenenitrile,
1,7-octadiene, 7-octen-1-al, acrylonitrile, acrylic
acid esters, methyl acrylate, methylacrylic acid
esters, methyl methacrylate, acrolein, and other
substituted ethylenically unsaturated compounds.</p>
    <p num="0021">A special class of internally unsaturated
organic compounds useful in the present process is
3-pentenenitrile, 3-pentenoic acid, and C1-C6 alkyl
3-pentenoate ester compounds. The linear aldehydes
prepared by the present process starting from this 
class of compounds may advantageously be used in the
preparation of e-caprolactam or adipic acid, which are
precursors for Nylon-6 and Nylon-6,6 respectively.
Examples of C1-C6 alkyl 3-pentenoates are methyl,
ethyl, isopropyl, tert-butyl-, pentenyl- and cyclohexyl
3-pentenoate. Methyl and ethyl 3-pentenoate esters are
preferred because they are more readily available.</p>
    <p num="0022">The 3-pentenenitrile, 3-pentenoic acid and
C1-C6 alkyl 3-pentenoate ester compounds may be present
in mixtures containing respectively: 2- and
4-pentenenitrile; 2- and 4-pentenoic acid; and C1-C6
alkyl 2- and 4-pentenoate ester compounds. Because
these compounds react in a similar fashion as their
corresponding 3-isomers to the desired linear aldehyde,
the mixture of isomers can be directly used in the
process according to the present invention.</p>
    <p num="0023">The reaction conditions of the
hydroformylation process according to this invention
are in general the same as used in a conventional
process, described for example in U.S. Pat. No.
4,769,498, and will be dependent on the particular
starting ethylenically unsaturated organic compound.
For example, the temperature can be from ambient
temperature to 200°C, preferably from about 50°C to
150°C, and more preferably from 90° to 110°C. The
pressure may vary from atmospheric pressure to 20 mPa,
preferably from 0.15 to 10 mPa, and more preferably
from 0.2 to 5 mPa. The pressure is, as a rule, equal
to the combined hydrogen and carbon monoxide partial
pressure. However, extra inert gasses may also be
present. The molar ratio of hydrogen: carbon monoxide
is generally between 10:1 and 1:10 and preferably
between 6:1 and 1:2.</p>
    <p num="0024">The formation of aldehydes by
hydroformylation, particularly in a continuous process,
often times produces high boiling products that are
formed from the condensation of the aldehyde reaction
products. These high boiling materials are 
particularly difficult to remove from the catalyst
reaction system (the combination of the phosphorous
bidentate ligand and the Group VIII metal ion). In
some cases the desired aldehyde product may, itself, be
high boiling and difficult to separate from the
catalyst system. The present invention provides,
through the proper selection of the ligand structure
for the catalyst system and the selective use of
solvents, a process in which the high boiling reaction
products and byproducts may be easily separated from
the catalyst system.</p>
    <p num="0025">In forming the catalyst system of the present
invention, the amount of Group VIII metal (compound) is
not specially limited, but is optionally selected so
that favorable results can be obtained with respect to
catalyst activity and process economy. In general, the
concentration of Group VIII metal in the reaction
medium is between 10 and 10,000 ppm and more preferably
between 50 and 500 ppm, calculated as free metal.
Although any Group VIII metal may be used in the
present process, rhodium is preferred.</p>
    <p num="0026">Although the molecular structure of the
ligand, as described below, is essential to the present
invention, the molar ratio of the phosphite ligand to
Group VIII metal is not specially limited, but is
optionally selected so that favorable results can be
obtained with respect to catalyst activity and desired
aldehyde selectivity. This ratio generally is from
about 0.5 to 100 and preferably from 1 to 10 (moles
ligand/mole metal).</p>
    <p num="0027">Although the ligand of the present invention
may be monodentate or bidentate, the preferred ligands
of the present invention are bidentate organic phosphite ligand
having two trivalent phosphorous atoms wherein the
ligand contains at least one C9 to C40 aliphatic group
positioned on the backbone or side arm ring structures
of the ligand. </p>
    <p num="0028">The structure of any ligand used in a
hydroformylation catalyst system is generally selected
such that backbone and side arms of the ligand
structure provide the desired selectivity and activity.
The term backbone refers to the bridging group between
the two phosphorus atoms, and the term side arms refer
the non-bridging groups attached to the phosphorus
atoms.</p>
    <p num="0029">Many backbone and side arm structures of
bidentate ligands known for the production of aldehydes
by hydroformylation may be modified for use in the
present invention by adding to the ligand at least one
C9 to C40 aliphatic group substituted for a hydrogen or
for some R group of the aromatic ring backbone or side
arm structure. Also ligands known for hydroformylation
that already have at least one C9 to C40 aliphatic
group on the backbone or side arm structures of the
ligand may be used in the present invention. By the
term modifying is meant the substitution of the
aliphatic group of the invention on a ligand already
synthesized or the changing the synthesis of the ligand
so that the final structure contains at least one C9 to
C40 aliphatic group.</p>
    <p num="0030">The ligand structures of the present invention
provide long chain aliphatic group or tails that extend
from the ligand structure causing the ligand to become
preferentially soluble in a non-polar solvent. The
substitution of the aliphatic group on a backbone or
side arm position will contribute little if any to a
change in the activity or selectivity of the ligand as
used in the catalyst system for hydroformylation. Thus
by adapting the ligand to be preferentially soluble in
a non-polar solvent, the present invention provides a
ligand property that can work together with the two
phase process solvent to make the separation of ligand
and product simple and easy, while maintaining the 
activity and selectivity of the basic ligand structure
(that is the activity and selectivity of the ligand not
having the substitution of a smaller group by a C9 to
C40 aliphatic group). Ligands of the following
structures are preferred in the present invention
because of their activity and selectivity towards
linear aldehydes. As noted below the basic structure
for Ligands I, II and III is structure A on the left;
the basic structure for Ligands IV to IX is structure
B on the right:
<img id="img-00110001" orientation="unknown" wi="151" img-format="tif" img-content="cf" file="00110001.tif" inline="no" he="82"/>
   where in Ligand I, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub> is H;
in Ligand II, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub> is CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub> ; in
Ligand III, R<sub>1</sub> and R<sub>2</sub> are (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> ; in Ligand IV, R<sub>1</sub> is
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> , R<sub>2</sub> is O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>3</sub> is H; in Ligand V, R<sub>1</sub>
is (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in Ligand VI, R<sub>1</sub> is
CH(CH<sub>3</sub>) (CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in Ligand VII, R<sub>1</sub>
is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is H and R<sub>3</sub> is OSi (CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; in
Ligand VIII, R<sub>1</sub> is CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>) ((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) and R<sub>2</sub> and
R<sub>3</sub> are H; and in Ligand IX is CH<sub>2</sub>CH(R<sub>4</sub>) (R<sub>5</sub>) and R<sub>4</sub> and R<sub>5</sub>
are the same or different hydrocarbons having from 6 to
30 carbon atoms.</p>
    <p num="0031">The second aspect of the present invention is
the use of a two phase process solvent. As described
below, the two phase solvent mixture or process solvent 
may be used in three ways in the practice of the
present invention. It may be used as the reaction
solvent; or one of the components of the two phase
solvent mixture may be used as the reaction solvent and
the other component added following the
hydroformylation to serve to extract and separate
reaction products from the catalyst system; or the
hydroformylation reaction may be carried out with the
ethylenically unsaturated compound also functioning as
the reaction solvent; then following the
hydroformylation, the two phase process solvent or
mixture is added to the reaction mixture to extract and
separate products from the catalyst system.</p>
    <p num="0032">Generally when one solvent does not dissolve
in another solvent, or when a first solvent has a low
or limited solubility in a second solvent, the two
solvents are said to be immiscible. When immiscible
solvents are mixed together, they separate into two
phases - the less dense phase floating on top of the
more dense phase. Also generally when a mixture of two
or more solvents form separate phases, one phase is
said to polar relative to the other. Polar and non-polar
are relative terms, but polar solvents are
generally those that contain electronegative atoms such
as oxygen or nitrogen, are of lower molecular weights
and mix with water. Non-polar solvents are those that
contain primarily hydrogen and carbon, that do not mix
with water and that mix readily with oil. As used
herein, the term polar means to hydrophilic or
lipophobic; while the term non-polar means hydrophobic
or lipophilic. Thus, a lipophilic ligand is one that is
preferentially soluble in a non-polar solvent or in the
more non-polar of a two solvent mixture.</p>
    <p num="0033">To form the two phase process solvent of the
present invention, one mixes a polar and a non-polar
solvent or mixtures of polar and non-polar solvents to
form two phases. One solvent or solvent mixture must be
more lipophilic than the other. As described above,
this two phase solvent mixture may be present as the 
initial reaction solvent for the hydroformylation. It
may be added as a two phase mixed solvent following the
hydroforymlation to function as an extraction medium.
Or in another way to practice the present invention, a
single solvent may be added to the reaction mixture
causing the formation of a two phase mixture from which
the desired component of the hydroformylation reaction
system may be isolated.</p>
    <p num="0034">In selecting solvent components for the two
phase solvent mixture, it is only essential that the
two components form two separate phases when mixed
together. The ligand structures of the present
invention, having extended aliphatic tails that may be
as long as C40, cause the ligand to be preferentially
soluble in the non-polar component of the two phase
solvent mixture. The present invention also allows for
the adjustment of the polarity of the ligand by the
choice of longer tails and a greater number of tails
being used to provide a more non-polar ligand.</p>
    <p num="0035">Examples of polar compounds suitable for
forming the two phase solvent mixture include water,
dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO),
methanol, ethanol, dimethylforamide (DMF), adiponitrile
(ADN), acetonitrile and N-methyl pyrrolidone(NMP).</p>
    <p num="0036">Compounds such as C5 to C20 hydrocarbons
including linear, branched, cyclic or aromatic
compounds are examples of compounds that may be used as
the non-polar component of the two phase solvent
mixture. Higher molecular weight alcohols, aldehydes,
esters or ketones may also be used as the non-polar
component. Examples of non-polar compounds suitable in
the process of the present invention include hexane,
cyclohexane, hexene, petroleum ethers and naphta. For
an aromatic solvent used in the practice of the present
invention, it is preferred that the aromatic solvent
molecule have aliphatic side chains to ensure that it
is non-polar enough to form a second phase when mixed
with the reaction products of the hydroformylation. </p>
    <p num="0037">If the reaction conditions are at sufficient
pressure, even C4 hydrocarbons could be used as the
non-polar component of the solvent mixture.</p>
    <p num="0038">In the practice of the present invention, a
non-polar solvent may be added to the reaction mixture
after the hydroformylation reaction is completed, but
before any products are isolated from the mixture.
Such a process would occur as follows: (a) reacting an
ethylenically unsaturated compound by hydroformylation
in the presence a solvent and the catalyst system of
the present invention, (b) adding a non-polar solvent
to the reaction product of step (a) so that two phases
are formed and allowing the catalyst system to be
extracted into the non-polar solvent, (c) isolation of
the non-polar solvent layer, (d) evaporation of the
non-polar solvent to isolate the catalyst system, (e)
returning the isolated catalyst system to step (a).</p>
    <p num="0039">Another way to practice the present invention
is by removing any volatiles, including reaction
products prior to addition of a non-polar solvent.
Such a process would occurs as follows: (a) reacting
an ethylenically unsaturated compound by
hydroformylation in the present of a polar solvent or
an excess of the ethylenically unsaturated compound and
the catalyst system of the present invention, (b)
removal of volatiles from the reaction media of step
(a), (c) dissolving the catalyst system in a non-polar
solvent such as a C5 to C20 hydrocarbon solvent so that
two layers are formed or adding a two phases solvent
mixture to the reaction mixture dissolving the catalyst
system in the non-polar phase, (d) isolation of the
non-polar solvent containing the catalyst system, (e)
evaporation of the hydrocarbon solvent to isolate the
catalyst system, (f) returning the isolated catalyst
system to step (a) and recovery of either solvent or
products distributed in the polar phase. In the case of
this method of practicing the present invention, the
reaction solvent may be an the olefinic reactant. </p>
    <p num="0040">In another way of practicing the present
invention, the reaction would be run in a two phase
reaction solvent. Following reaction, the phase can be
separated by conventional means and the product
recovered and the catalyst may be recycled for further
reaction.</p>
    <p num="0041">The extraction step in the present invention
may be carried out at room temperature and atmospheric
pressure or at other conditions that are suitable in
the overall processing of batch or continuous
hydroformylation operations. For example, pressures
for extraction may be from 0.1 to 1 Pa, with a range of
0.1 to 0.2 Pa being preferred, and temperatures for the
extraction may be from 0 to 120°C, with a preferred
range from 15 to 50°C.</p>
    <p num="0042">The preferred way to practice the present
invention is to allow the hydroformylation reaction to
take place in an excess of the ethylenically
unsaturated compound. Then following the
hydroformylation reaction to add a two phase solvent
mixture to partition and extract the reaction products
in the polar phase of the solvent mixture and the
catalyst system in the non-polar phase.</p>
    <p num="0043">The process of this invention may be run in
either a continuous or batch mode. In general for
large scale industrial processes, a continuous mode is
preferred, while batch mode is more practical for
smaller scale reactions.</p>
    <p num="0044">The invention is illustrated by but not
intended to be limited to the following examples. </p>
    <heading>
      <b>
        <u style="single">EXAMPLES</u>
      </b>
    </heading>
    <heading>
      <b>
        <u style="single">Synthesis of a lipophilic ligand:</u>
      </b>
    </heading>
    <p num="0045">
      <img id="img-00160001" orientation="unknown" wi="164" img-format="tif" img-content="cf" file="00160001.tif" inline="no" he="36"/>
      <img id="img-00160002" orientation="unknown" wi="159" img-format="tif" img-content="cf" file="00160002.tif" inline="no" he="55"/>
    </p>
    <p num="0046">The synthesis of ligand-I was carried out in
the following series of steps forming compounds A to
E.</p>
    <heading>I. <u style="single">Synthesis of tert-Butyldimethylsilyl 3</u></heading>
    <heading>
      <u style="single">(tert-butyldimethylsilyloxy)-2-naphthoate.</u>
    </heading>
    <p num="0047"><u style="single">Compound A:</u> To a solution of 30 g (0.16 mol) of
3-hydroxy-2-naphthoic acid and 51 g (0.34 mol) of tertbutyldimethylsilyl
chloride in 600 mL of
tetrahydrofuran was added dropwise 64 g (0.64 mol) of
triethylamine under nitrogen. The mixture was stirred
for four hours at room temperature, triethylamine
hydrochloride was filtered, and the solvent was
evaporated. The residue was poured into water (500 mL)
and extracted with petroleum ether (500 mL). The
organic layer was washed with saturated aqueous sodium
bicarbonate, dried over magnesium sulfate and filtered.
The solvent was evaporated under vacuum to yield 58 g
(87%) of (A) as a yellow liquid.</p>
    <heading>II. <u style="single">Synthesis of decyl 3-(tert-Butyldimethylsilyloxy)-2-naphthoate
(Compound B):</u></heading>
    <p num="0048">Under 
nitrogen, 17.5 mL (0.20 mol) of oxalyl chloride were
added dropwise to a solution of 58 g (0.14 mol) of
Compound A in 300 mL of dichloromethane containing 60
drops of dimethylformamide. The mixture was stirred
overnight at room temperature, and then the solvent was
evaporated under vacuum. To the residue was slowly
added a solution of 24 g (0.15 mole) of 1-decanol and
33 g (0.42 mol) of pyridine in 200 ml of diethyl ether
under nitrogen. The mixture was stirred overnight at
room temperature. Then the pyridinium hydrochloride
was filtered and the solvent was evaporated under
vacuum. Hexane was added, the mixture was stirred for
5 minutes and then filtered through silica gel. Hexane
was evaporated under vacuum to yield 62 g of Compound B
as a yellow liquid.</p>
    <heading>III. <u style="single">Synthesis of decyl-3-hydroxy-2-naphtoate
(Compound C):</u></heading>
    <p num="0049">To a solution of 49 g (0.11
mol) of Compound B in 300 mL of tetrahydrofuran was
added a solution of 80 g (0.25 mol) of
tetrabutylammonium fluoride in 200 mL of
tetrahydrofuran. The mixture was stirred for one hour
at room temperature, and then the solvent was
evaporated under vacuum. The residue was dissolved in
dichloromethane and washed with aqueous ammonium
chloride and saturated aqueous sodium bicarbonate. The
organic layer was dried over magnesium sulfate and
filtered before the solvent was evaporated. The
product, Compound C, was purified by filtration over
silica gel using 3% ether/hexane as the eluent. Yield
92%.</p>
    <heading>IV. <u style="single">Synthesis of 4,4'-Bi-decyl 3-hydroxy-2-naphthoate
(Compound D):</u></heading>
    <p num="0050">To a solution of 23 g (0.071
mol) of Compound C in 400 mL toluene was added 1.6 g
(7.1 mmol) of Cu(OH)Cl-TMEDA where TMEDA stands for
N,N,N',N'-tetramethylethylenediamine. The reaction
mixture was heated at 100°C under an atmosphere of
oxygen overnight, and the progress of the reaction was
monitored by thin layer chromatography. Once Compound 
C was totally converted, the reaction mixture was
filtered through silica gel, rinsed with
dichloromethane before removing the solvent under
vacuum. Recrystallization from methanol gave 21 g
(91%) of Compound D as yellow crystals.</p>
    <heading>V. <u style="single">Synthesis of Bis (2-isopropylphenyl)phosphorochloridite (Compound E) :</u></heading>
    <p num="0051">To a
solution of 20 g (0.15 mol) of 2-isopropylphenol and
16 g (0.16 mol) of triethylamine in 200 ml of hexane
was slowly added a solution of 14.8 g (0.07 mol) of
diisopropylphosphoramidous dichloride in 200 mL of
hexane. The mixture was stirred overnight at room
temperature, then filtered through alumina and washed
with dichloromethane. The solvent was removed under
vacuum, and the residue (9 g, 0.027 mol) was dissolved
in 200 mL of cyclohexane. Dry HCl was bubbled through
the solution for one hour. The excess HCl was purged
by bubbling nitrogen through the reaction mixture. The
reaction mixture was then transferred into a dry box.
The diethylamine hydrochloride filtered, and the
solution evaporated under vacuum to give 6.2 g of
Compound E as a yellow oil.</p>
    <p num="0052"><u style="single">Ligand-I:</u> 5 ml of tetrahydrofuran was added
dropwise along with a solution of 4 g (0.006 mole) of
Compound D and 2.3 g (0.02 mol) of triethylamine in 50
mL of tetrahydrofuran under nitrogen to a solution of
6.2 g (0.018 mol) of Compound E,. The reaction mixture
was stirred overnight at room temperature, filtered and
evaporated. The reside was treated with 10 mL
isopropyl alcohol and 2 g of triethylamine. After
stirring for one hour, the solvent was evaporated,
pentane was added and the mixture filtered through
alumina. Recrystallization from pentane gave 5 g of
Ligand-I as white crystals.</p>
    <heading>
      <b>
        <u style="single">EXAMPLE 1: Hydroformylation in a Two phase Solvent</u>
      </b>
    </heading>
    <p num="0053">A solution containing 0.28 g of Ligand-I,
0.032 g of rhodiumdicarbonylacetylacetonate, 1.44 g of 
O-dichlorobenzene (internal standard) and 30.31 g of
methyl 3-pentenoate were mixed with 29.92 g of octane
(non-polar component) and 30.87 g of adiponitrile
(polar component). This two phase system was loaded
into a 100 mL autoclave and heated with vigorous
stirring under 150 psi CO/H2(1:1) at 105°C for 8 hours.
A GC sample was taken after 8 hours and homogenized by
adding acetone. The analysis shows (mole%):methyl
4-pentenoate (M4P) 0.63%, methyl 2-pentenoate (M2P)
4.91%, methyl valerate (MV) 4.96%, methyl 3-pentenoate
(M3P) 13.92%, methyl 3-formylvalerate (3FMVA) 2.89%,
methyl 4-formylvalerate (4FMVA) 3.25%, methyl 5-formylvalerate
(5FMVA) 68.87%. Once the autoclave
reached 30°C, the content was transferred into a
nitrogen purged dry box. The phases were separated and
analyzed by X-ray Florescence (XFR) for Rh and P. Top
phase 590 ppm P, 433 ppm Rh; bottom phase 20 ppm P, 10
ppm Rh. GC analysis: Top phase (octane) M4P 0.0%, M2P
13.49%, MV 19.08%, M3P 35.29%, 3FMVA 1.95%, 4FMVA
1.85%, 5FMVA 28.34%; Bottom phase (adiponitrile) M4P
0.5%, M2P 3.93%, MV 3.58%, M3P 12.1%, 3FMVA 2.99%,
4FMVA 3.42%, 5FMVA 73.48%; moles top phase/moles bottom
phase=7.7/92.3.</p>
    <heading>
      <b>
        <u style="single">EXAMPLE 2: Catalyst extraction and recycle</u>
      </b>
    </heading>
    <p num="0054">A solution containing 0.448 g of Ligand-I,
0.044 g of rhodiumdicarbonylditertbutylacetylacetonate
and 65.054 g of methyl-3-pentenoate was loaded into a
100 mL autoclave and heated with vigorous stirring
under 150 psi CO/H2(1:1) at 105°C for 8 hours. Once
the autoclave reached 30°C the content was transferred
into a nitrogen purged dry box. The effluent (reaction
mixture) from the autoclave was weighed and combined
with equal weights of hexane and acetonitrile (two
phase process solvent). The top layer was saved and
the bottom layer extracted twice with the same amount
of hexane. All the hexane layers were combined and
under high vacuum hexane was removed. Methyl 3-pentenoate 
was added to the residue as shown in Table 1
and the hydroformylation reaction was run again. A
100uL sample was taken each cycle to monitor the
performance of the catalyst upon recycle. Table 2
indicates the composition (mmol/g) as a function of
cycle number.
<tables><table><tgroup cols="5"><tbody><row><entry align="center"/><entry align="left"><b>W<sub>residue</sub> (g)</b></entry><entry align="left"><b>M3P (g)</b></entry><entry align="left"><b>W<sub>out</sub>-W<sub>in</sub> (g)</b></entry><entry align="left"><b>Time (h)</b></entry></row><row><entry align="left">Cycle #1</entry><entry align="right"/><entry align="center">65.06</entry><entry align="center">8.27</entry><entry align="center">6.00</entry></row><row><entry align="left">Cycle #2</entry><entry align="center">9.86</entry><entry align="center">64.70</entry><entry align="center">9.13</entry><entry align="center">6.00</entry></row><row><entry align="left">Cycle #3</entry><entry align="center">16.05</entry><entry align="center">66.53</entry><entry align="center">11.60</entry><entry align="center">8.00</entry></row><row><entry align="left">Cycle #4</entry><entry align="center">18.09</entry><entry align="center">54.67</entry><entry align="center">13.16</entry><entry align="center">8.00</entry></row><row><entry align="left">Cycle #5</entry><entry align="center">8.79</entry><entry align="center">61.58</entry><entry align="center">8.88</entry><entry align="center">6.00</entry></row><row><entry align="left">Cycle #6</entry><entry align="center">8.85</entry><entry align="center">61.72</entry><entry align="center">8.11</entry><entry align="center">6.00</entry></row><row><entry align="left">Cycle #7</entry><entry align="center">7.00</entry><entry align="center">67.28</entry><entry align="center">7.95</entry><entry align="center">6.00</entry></row></tbody></tgroup></table></tables><tables><table><tgroup cols="8"><tbody><row><entry align="center"/><entry align="left">M4P</entry><entry align="left">M2P</entry><entry align="left">MV</entry><entry align="left">M3P</entry><entry align="left">3FMVA</entry><entry align="left">4FMVA</entry><entry align="left">5FMVA</entry></row><row><entry align="left">Cycle #1</entry><entry align="center">0.11</entry><entry align="center">0.40</entry><entry align="center">0.15</entry><entry align="center">1.92</entry><entry align="center">0.22</entry><entry align="center">0.26</entry><entry align="center">4.25</entry></row><row><entry align="left">Cycle #2</entry><entry align="center">0.10</entry><entry align="center">0.41</entry><entry align="center">0.14</entry><entry align="center">2.50</entry><entry align="center">0.20</entry><entry align="center">0.24</entry><entry align="center">3.65</entry></row><row><entry align="left">Cycle #3</entry><entry align="center">0.12</entry><entry align="center">0.41</entry><entry align="center">0.13</entry><entry align="center">3.17</entry><entry align="center">0.19</entry><entry align="center">0.23</entry><entry align="center">3.22</entry></row><row><entry align="left">Cycle #4</entry><entry align="center">0.11</entry><entry align="center">0.46</entry><entry align="center">0.16</entry><entry align="center">2.13</entry><entry align="center">0.23</entry><entry align="center">0.28</entry><entry align="center">4.01</entry></row><row><entry align="left">Cycle #5</entry><entry align="center">0.08</entry><entry align="center">0.39</entry><entry align="center">0.13</entry><entry align="center">2.49</entry><entry align="center">0.21</entry><entry align="center">0.25</entry><entry align="center">3.08</entry></row><row><entry align="left">Cycle #6</entry><entry align="center">0.12</entry><entry align="center">0.38</entry><entry align="center">0.12</entry><entry align="center">2.69</entry><entry align="center">0.20</entry><entry align="center">0.24</entry><entry align="center">3.90</entry></row><row><entry align="left">Cycle #7</entry><entry align="center">0.14</entry><entry align="center">0.37</entry><entry align="center">0.12</entry><entry align="center">3.29</entry><entry align="center">0.23</entry><entry align="center">0.26</entry><entry align="center">3.99</entry></row></tbody></tgroup></table></tables></p>
    <heading>
      <b>
        <u style="single">EXAMPLE 3:</u>
      </b>
    </heading>
    <p num="0055">The following example illustrates a high
boiler purge in the process of the present invention.
A 100 mL autoclave was charged with 80 g of a solution
prepared dissolving 1.31 g of Ligand-V, described
above, 0.054 of rhodiumdicarbonylacetyl-acetonate and
100 g of methyl 3-pentenoate (excess ethylenically
unsaturated compound). The autoclave heated with
vigorous stirring under 150 psi CO/H2(1:1) at 105°C for 
5 hours. Once the autoclave reached 30°C the content
was transferred into a nitrogen purged dry box and the
product distilled under high vacuum. The residue
(including high boiling byproducts and the catalyst
system) was dissolved in methyl 3-pentenonate and the
hydroformylation experiment repeated 10 times. The
analysis for the 10 experiments is shown in Table 3.
The residue (polar solvent) (17.2 g) from cycle 10 was
combined with 75 ml of hexane (addition of a non-polar
phase to form the process solvent). The phases were
separated and the bottom layer was extracted twice with
75 mL of hexane. The hexane extracts were combined,
hexane was removed under vacuum and the residue (1.1 g)
was dissolved in methyl 3-pentenoate. The bottom layer
weighed 15.6 g indicating 90% efficiency for the
removal of high boilers. The hydroformylation
experiment was repeated again. The analysis for this
experiment, Cycle 11, is also shown in Table 3. Table
3 indicates the composition (mmol/g) as a function of
cycle number.
<tables><table><tgroup cols="10"><tbody><row><entry align="center"/><entry align="left">M4P</entry><entry align="left">Mc2P</entry><entry align="left">MV</entry><entry align="left">M3P</entry><entry align="left">Mt2P</entry><entry align="left">M2FV</entry><entry align="left">M3FV</entry><entry align="left">M4FV</entry><entry align="left">M5FV</entry></row><row><entry align="left">Cycle #1</entry><entry align="center">0.00</entry><entry align="center">0.01</entry><entry align="center">0.25</entry><entry align="center">0.32</entry><entry align="center">0.35</entry><entry align="center">0.06</entry><entry align="center">0.18</entry><entry align="center">0.24</entry><entry align="center">5.03</entry></row><row><entry align="left">Cycle #2</entry><entry align="center">0.01</entry><entry align="center">0.02</entry><entry align="center">0.29</entry><entry align="center">0.42</entry><entry align="center">0.57</entry><entry align="center">0.05</entry><entry align="center">0.15</entry><entry align="center">0.26</entry><entry align="center">4.68</entry></row><row><entry align="left">Cycle #3</entry><entry align="center">0.00</entry><entry align="center">0.02</entry><entry align="center">0.26</entry><entry align="center">0.36</entry><entry align="center">0.45</entry><entry align="center">0.09</entry><entry align="center">0.20</entry><entry align="center">0.29</entry><entry align="center">4.78</entry></row><row><entry align="left">Cycle #4</entry><entry align="center">0.00</entry><entry align="center">0.01</entry><entry align="center">0.24</entry><entry align="center">0.31</entry><entry align="center">0.45</entry><entry align="center">0.05</entry><entry align="center">0.20</entry><entry align="center">0.30</entry><entry align="center">4.23</entry></row><row><entry align="left">Cycle #5</entry><entry align="center">0.01</entry><entry align="center">0.01</entry><entry align="center">0.24</entry><entry align="center">0.38</entry><entry align="center">0.39</entry><entry align="center">0.04</entry><entry align="center">0.20</entry><entry align="center">0.28</entry><entry align="center">4.61</entry></row><row><entry align="left">Cycle #6</entry><entry align="center">0.01</entry><entry align="center">0.01</entry><entry align="center">0.24</entry><entry align="center">0.36</entry><entry align="center">0.30</entry><entry align="center">0.07</entry><entry align="center">0.21</entry><entry align="center">0.26</entry><entry align="center">4.31</entry></row><row><entry align="left">Cycle #7</entry><entry align="center">0.01</entry><entry align="center">0.02</entry><entry align="center">0.26</entry><entry align="center">0.33</entry><entry align="center">0.61</entry><entry align="center">0.04</entry><entry align="center">0.13</entry><entry align="center">0.27</entry><entry align="center">3.55</entry></row><row><entry align="left">Cycle #8</entry><entry align="center">0.01</entry><entry align="center">0.02</entry><entry align="center">0.29</entry><entry align="center">0.33</entry><entry align="center">0.64</entry><entry align="center">0.06</entry><entry align="center">0.12</entry><entry align="center">0.28</entry><entry align="center">4.02</entry></row><row><entry align="left">Cycle #9</entry><entry align="center">0.01</entry><entry align="center">0.01</entry><entry align="center">0.23</entry><entry align="center">0.32</entry><entry align="center">0.31</entry><entry align="center">0.14</entry><entry align="center">0.16</entry><entry align="center">0.22</entry><entry align="center">4.18</entry></row><row><entry align="left">Cycle #10</entry><entry align="center">0.01</entry><entry align="center">0.02</entry><entry align="center">0.27</entry><entry align="center">0.39</entry><entry align="center">0.51</entry><entry align="center">0.02</entry><entry align="center">0.11</entry><entry align="center">0.20</entry><entry align="center">3.96</entry></row><row><entry align="left">Cycle #11</entry><entry align="center">0.01</entry><entry align="center">0.02</entry><entry align="center">0.31</entry><entry align="center">0.57</entry><entry align="center">0.40</entry><entry align="center">0.05</entry><entry align="center">0.17</entry><entry align="center">0.22</entry><entry align="center">4.73</entry></row></tbody></tgroup></table></tables></p>
  </description>
  <claims load-source="patent-office" status="new" mxw-id="PCLM11592285" lang="DE">
    <claim num="1">
      <claim-text>Verfahren zur Herstellung eines linearen Aldehyd, umfassend das Umsetzen einer
ethylenisch ungesättigten Verbindung durch Hydroformylierung in Gegenwart eines
Katalysatorsystems, das zusammengesetzt ist aus einem Metall der Gruppe VIII, einem
organischen Phosphit-Liganden und einem Reaktionslösemittel, worin der organische
Phosphit-Ligand ein Ligand ist, der Phosphor mit der Struktur (PR<sub>2</sub>)<sub>n</sub>R' enthält, worin n 2
ist, R und R' sind organische Reste, die gleich oder verschieden sein können, und worin R
oder R' mindestens eine C<sub>9</sub>- bis C<sub>40</sub>-aliphatische Gruppe enthalten, die sich an einem von
der primären Ligandenstruktur weggestreckten Endstück befindet, die den Liganden
lipophil machen, und worin das Reaktionslösemittel eine zweiphasige Mischung einer
organischen Verbindung mit 5 bis 20 Kohlenstoffatomen und ein polares Lösemittel ist.</claim-text>
    </claim>
    <claim num="2">
      <claim-text>Verfahren zur Hydroformylierung einer ethylenisch ungesättigten Verbindung, bei
welchem die Reaktionsprodukte und einschließlich hochsiedende Reaktionsprodukte von
dem Katalysatorsystem leicht abgetrennt werden, welches Verfahren die Schritte umfasst:
<claim-text><claim-text>(a) Zur Erzeugung eines Reaktionsgemisches in einem Reaktionslösemittel
Umsetzen der ethylenisch ungesättigten Verbindung in Gegenwart eines
Katalysatorsystems, das zusammengesetzt ist aus einem Metall der Gruppe VIII und
einem organischen Phosphit-Liganden, enthaltend Phosphor mit der Struktur (PR<sub>2</sub>)<sub>n</sub>R',
worin n gleich 2 ist, R und R' sind organische Reste, die gleich oder verschieden sein
können, und worin R oder R' mindestens eine C<sub>9</sub>- bis C<sub>40</sub>-aliphatische Gruppe enthalten,
die sich an einem von der primären Ligandenstruktur weggestreckten Endstück befindet,
die den Liganden lipophil machen;</claim-text><claim-text>(b) Zusetzen eines nichtpolaren Lösemittels zum Reaktionsgemisch, um zwei
Phasen zu erzeugen, von denen eine eine polare Phase ist, die überwiegend aus den
Reaktionsprodukten gebildet wird, und die andere eine solche, die überwiegend aus dem
nichtpolaren Lösemittel und dem Katalysatorsystem gebildet wird, so dass die
Reaktionsprodukte und einschließlich die hochsiedenden Reaktionsprodukte der
Hydroformylierung in der polaren Phase bleiben und das Katalysatorsystem weitgehend
in die nichtpolare Phase abgetrennt ist; sowie</claim-text><claim-text>(c) Abtrennen der zwei Phasen und Isolieren der Reaktionsprodukte aus der
polaren Phase und des Katalysators aus der nichtpolaren Phase.</claim-text></claim-text></claim-text>
    </claim>
    <claim num="3">
      <claim-text>Verfahren nach Anspruch 1 oder 2, bei welchem das Reaktionslösemittel die
ethylenisch ungesättigte Verbindung ist.</claim-text>
    </claim>
    <claim num="4">
      <claim-text>Verfahren nach Anspruch 2, bei welchem vor dem Zusatz des nichtpolaren
Lösemittels von Schritt (b) die flüchtigen Bestandteile aus dem Reaktionsgemisch von
Schritt (a) entfernt werden. </claim-text>
    </claim>
    <claim num="5">
      <claim-text>Verfahren nach Anspruch 2, bei welchem die Schritte (a) und (b) vereint werden
und die Hydroformylierung in einem zweiphasigen Reaktionslösemittel ausgeführt wird.</claim-text>
    </claim>
    <claim num="6">
      <claim-text>Verfahren nach Anspruch 2, bei welchem der zurückgewonnene Katalysator in
Schritt (a) zurückgeführt wird und die Schritte wiederholt werden.</claim-text>
    </claim>
    <claim num="7">
      <claim-text>Verfahren nach Anspruch 1 oder 2, bei welchem das nichtpolare Lösemittel
ausgewählt wird aus der Gruppe von C<sub>5</sub>- bis C<sub>20</sub>-Kohlenwasserstoff-Lösemitteln.</claim-text>
    </claim>
    <claim num="8">
      <claim-text>Verfahren nach einem der Ansprüche 1 oder 2, bei welchem die ethylenisch
ungesättigte Verbindung ausgewählt wird aus der Gruppe, bestehend aus 3-Pentensäure,
C<sub>1</sub>- bis C<sub>6</sub>-Alkylestern von 3-Pentensäure, 3-Pentennitril und 4-Pentennitril.</claim-text>
    </claim>
    <claim num="9">
      <claim-text>Verfahren nach Anspruch 1 oder 2, bei welchem der organische Ligand
ausgewählt wird aus den Strukturen A und B
<img id="img-00280001" orientation="unknown" wi="137" img-format="tif" img-content="cf" file="00280001.tif" inline="no" he="63"/>
worin die Strukturen A für die Liganden I bis III und die Strukturen B für die Liganden
IV und IX stehen, Ligand I: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> und R<sub>2</sub> ist H; Ligand II: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>
und R<sub>2</sub> ist CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; Ligand III: R<sub>1</sub> und R<sub>2</sub> sind (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; Ligand IV: R<sub>1</sub> ist
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> ist O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> und R<sub>3</sub> ist H; Ligand V: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> und R<sub>2</sub> und R<sub>3</sub>
sind H; Ligand VI: R<sub>1</sub> ist CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> und R<sub>2</sub> und R<sub>3</sub> sind H; Ligand VII: R<sub>1</sub> ist
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> ist H und R<sub>3</sub> ist OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; Ligand VIII: R<sub>1</sub> ist
CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) und R<sub>2</sub> und R<sub>3</sub> sind H; sowie Ligand IX ist
CH<sub>2</sub>CH(R<sub>4</sub>)(R<sub>5</sub>) und R<sub>4</sub> und R<sub>5</sub> sind gleiche oder verschiedene Kohlenwasserstoffe mit 6
bis 30 Kohlenstoffatomen.</claim-text>
    </claim>
    <claim num="10">
      <claim-text>Verbessertes Verfahren zur Hydroformylierung zur Herstellung eines linearen
Aldehyds aus einem Reaktionsgemisch, enthaltend eine ethylenisch ungesättigte
Verbindung und ein Katalysatorsystem, das zusammengesetzt ist aus einem Metall der
Gruppe VIII und einem zweizähnigen organischen Phosphit-Liganden mit zwei
dreiwertigen Phosphoratomen, worin die ethylenisch ungesättigte Verbindung auch als
Reaktionslösemittel fungiert, wobei die Verbesserung umfasst: Erzeugen des
Katalysatorsystems aus einem Liganden, der mindestens eine C<sub>9</sub>- bis C<sub>40</sub>-aliphatische
Gruppe enthält, die sich an dem Grundgerüst- oder Nebenarm-Ringstrukturen des
Liganden befindet, und nach der Hydroformylierung der ethylenisch ungesättigten 
Verbindung Zusetzen des Reaktionsgemisches zu einem zweiphasigen
Lösemittelgemisch, bestehend aus einer polaren und einer nichtpolaren Komponente, so
dass die Reaktionsprodukte der Hydroformylierung in die polare Phase des
Lösemittelgemisches extrahiert werden und das Katalysatorsystem weitgehend in der
nichtpolaren Phase des Lösemittelgemisches zurückbleibt.</claim-text>
    </claim>
    <claim num="11">
      <claim-text>Verfahren nach Anspruch 10, bei welchem das nichtpolare Lösemittel ausgewählt
wird aus der Gruppe von C<sub>5</sub>- bis C<sub>20</sub>-Kohlenwasserstoff-Lösemitteln.</claim-text>
    </claim>
    <claim num="12">
      <claim-text>Verfahren nach Anspruch 10, bei welchem die ethylenisch ungesättigte
Verbindung ausgewählt wird aus der Gruppe, bestehend aus 3-Pentensäure, C<sub>1</sub>- bis C<sub>6</sub>-Alkylestern
von 3-Pentensäure, 3-Pentennitril und 4-Pentennitril.</claim-text>
    </claim>
    <claim num="13">
      <claim-text>Verfahren nach Anspruch 10, bei welchem der organische Ligand ausgewählt
wird aus den Strukturen A und B
<img id="img-00290001" orientation="unknown" wi="143" img-format="tif" img-content="cf" file="00290001.tif" inline="no" he="63"/>
worin die Strukturen A für die Liganden I bis III und die Strukturen B für die Liganden
IV und IX stehen; Ligand I: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> und R<sub>2</sub> ist H; Ligand II: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>
und R<sub>2</sub> ist CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; Ligand III: R<sub>1</sub> und R<sub>2</sub> sind (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; Ligand IV: R<sub>1</sub> ist
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> ist O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> und R<sub>3</sub> ist H; Ligand V: R<sub>1</sub> ist (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> und R<sub>2</sub> und R<sub>3</sub>
sind H; Ligand VI: R<sub>1</sub> ist CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> und R<sub>2</sub> und R<sub>3</sub> sind H; Ligand VII: R<sub>1</sub> ist
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> ist H und R<sub>3</sub> ist OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; Ligand VIII: R<sub>1</sub> ist
CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) und R<sub>2</sub> und R<sub>3</sub> sind H; und Ligand IX ist
CH<sub>2</sub>CH(R<sub>4</sub>)(R<sub>5</sub>) und R<sub>4</sub> und R<sub>5</sub> sind gleiche oder verschiedene Kohlenwasserstoffe mit 6
bis 30 Kohlenstoffatomen.</claim-text>
    </claim>
    <claim num="14">
      <claim-text>Verfahren nach Anspruch 1, 2 oder 10, bei welchem das Metall der Gruppe VIII
Rhodium ist.</claim-text>
    </claim>
  </claims>
  <claims load-source="patent-office" status="new" mxw-id="PCLM11592286" lang="EN">
    <claim num="1">
      <claim-text>A process for preparation of a linear
aldehyde comprising reacting an ethylenically
unsaturated compound by hydroformylation in the
presence of a catalyst system composed of a Group VIII
metal, an organic phosphite ligand and a reaction solvent wherein
the organic phosphite ligand is a ligand containing phosphorous
having the structure (PR<sub>2</sub>)<sub>n</sub>R' where n is
2, R and R' are organic residues which may be
the same or different and where the R or R' contain at
least one C9 to C40 aliphatic group positioned as a
tail extending away from the primary ligand structure
rendering the ligand lipophilic and wherein the
reaction solvent is a two phase mixture of an organic
compound having from 5 to 20 carbon atoms and polar
solvent.</claim-text>
    </claim>
    <claim num="2">
      <claim-text>A process for hydroformylation of an
ethylenically unsaturated compound wherein reaction
products including high boiling reaction products are
easily separated from the catalyst system comprising
the steps of:
<claim-text><claim-text>(a) reacting in a reaction solvent to form a
reaction mixture the ethylenically unsaturated compound
in the presence of a catalyst system composed of a
Group VIII metal and organic phosphite ligand containing
phosphorous having the structure (PR<sub>2</sub>)<sub>n</sub>R' where n is
2, R and R' are organic residues
which may be the same or different and where the R or
R' contain at least one C9 to C40 aliphatic group
positioned as a tail extending away from the primary
ligand structure rendering the ligand lipophilic;</claim-text><claim-text>(b) adding a non-polar solvent to the
reaction mixture to form two phases, one a polar phase
predominately formed from the reaction products and one
formed predominately from the non-polar solvent and the
catalyst system such that the reaction products
including the high boiling reaction products of the 
hydroformylation remain in the polar phase and the
catalyst system is partitioned substantially into the
non-polar phase; and</claim-text><claim-text>(c) separating the two phases and isolating
the reaction products from the polar phase and the
catalyst from the non-polar phase.</claim-text></claim-text></claim-text>
    </claim>
    <claim num="3">
      <claim-text>The process of claim 1 or 2 wherein the
reaction solvent is the ethylenically unsaturated
compound.</claim-text>
    </claim>
    <claim num="4">
      <claim-text>The process of claim 2 wherein volatile
are removed from the reaction mixture of step (a)
before the addition of the polar solvent of step (b).</claim-text>
    </claim>
    <claim num="5">
      <claim-text>The process of claim 2 wherein steps (a)
and (b) are combined and the hydroformylation is
carried out in a two phase reaction solvent.</claim-text>
    </claim>
    <claim num="6">
      <claim-text>The process of claim 2 wherein the
recovered catalyst is returned to step (a) and the
steps are repeated.</claim-text>
    </claim>
    <claim num="7">
      <claim-text>The process of claim 1 or 2 wherein the
non-polar solvent is chosen from the group of C5 to C20
hydrocarbon solvents.</claim-text>
    </claim>
    <claim num="8">
      <claim-text>The process of any one of claims 1 or 2,
wherein the ethylenically unsaturated compound is
chosen from the group consisting of 3-pentenoic acid,
C1 to C6 alkyl esters of 3-pentenoic acid,
3-pentenenitrile, and 4-penenenitrile. </claim-text>
    </claim>
    <claim num="9">
      <claim-text>The process of claim 1 or 2 wherein the
organic ligand is chosen from the structures A and B
<img id="img-00240001" orientation="unknown" wi="155" img-format="tif" img-content="cf" file="00240001.tif" inline="no" he="65"/>
wherein structures A for Ligands I to III and
structures B for Ligands IV to IX, Ligand I, R<sub>1</sub> is
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub> is H; Ligand II, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub>
is CO(CH<sub>2</sub>)CH<sub>3</sub> ; Ligand III is R<sub>1</sub> and R<sub>2</sub> are (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
Ligand IV, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is O(OH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>3</sub> is H;
in Ligand V, R<sub>1</sub> is (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in
Ligand VI, R<sub>1</sub> is CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in
Ligand VII, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is H and R<sub>3</sub> is
OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; in Ligand VIII, R<sub>1</sub> is
CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>) ((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) and R<sub>2</sub> and R<sub>3</sub> are H; and in
Ligand IX is CH<sub>2</sub>CH(R<sub>4</sub>) (R<sub>5</sub>) and R<sub>4</sub> and R<sub>5</sub> are the same or
different hydrocarbons having from 6 to 30 carbon
atoms</claim-text>
    </claim>
    <claim num="10">
      <claim-text>An improved hydroformylation process for
preparation of a linear aldehyde from a reaction
mixture containing an ethylenically unsaturated
compound and a catalyst system composed of a Group VIII
metal and a bidentate organic phosphite ligand having two
trivalent phosphorous atoms wherein the ethylenically
unsaturated compound also functions as reaction
solvent, the improvement comprising: forming the
catalyst system from a ligand containing at least one
C9 to C40 aliphatic group positioned on the backbone or
side arm ring structures of the ligand and following
hydroformylation of the ethylenically unsaturated 
compound adding to the reaction mixture a two phase
solvent mixture consisting of a polar and a non-polar
component so that the reaction products of the
hydroformylation are extracted into the polar phase of
the solvent mixture and the catalyst system remains
substantially in the non-polar phase of the solvent
mixture.</claim-text>
    </claim>
    <claim num="11">
      <claim-text>The process of claim 10 wherein the non-polar
solvent is chosen from the group of C5 to 20
hydrocarbon solvents.</claim-text>
    </claim>
    <claim num="12">
      <claim-text>The process of claim 10 wherein the
ethylenically unsaturated compound is chosen from the
group consisting of 3-pentenoic acid, C1 to C6 alkyl
esters of 3-pentenoic acid, 3-pentenenitrile, and 4-penetenenitrile.</claim-text>
    </claim>
    <claim num="13">
      <claim-text>The process of claim 10 wherein the
organic ligand is chosen from the structures A and B
<img id="img-00250001" orientation="unknown" wi="153" img-format="tif" img-content="cf" file="00250001.tif" inline="no" he="65"/>
wherein structures A for Ligands I to III and
structures B for Ligands IV to IX, Ligand I, R<sub>1</sub> is
(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub> is H; Ligand II, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>2</sub>
is CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub> ; Ligand III is R<sub>1</sub> and R<sub>2</sub> are (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
Ligand IV, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> , R<sub>2</sub> is O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> and R<sub>3</sub> is
H; in Ligand V, R<sub>1</sub> is (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in
Ligand VI, R<sub>1</sub> is CH(CH<sub>3</sub>) (CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> and R<sub>2</sub> and R<sub>3</sub> are H; in 
Ligand VII, R<sub>1</sub> is (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> is H and R<sub>3</sub> is
OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; in Ligand VIII, R<sub>1</sub> is
CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>) ((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) and R<sub>2</sub> and R<sub>3</sub> are H; and in
Ligand IX is CH<sub>2</sub>CH(R<sub>4</sub>) (R<sub>5</sub>) and R<sub>4</sub> and R<sub>5</sub> are the same or
different hydrocarbons having from 6 to 30 carbon
atoms.</claim-text>
    </claim>
    <claim num="14">
      <claim-text>The process as in claim 1, 2 or 10 wherein
the Group VIII metal is rhodium.</claim-text>
    </claim>
  </claims>
  <claims load-source="patent-office" status="new" mxw-id="PCLM11592287" lang="FR">
    <claim num="1">
      <claim-text>Procédé pour la préparation d'un aldéhyde linéaire comprenant la réaction d'un
composé éthyléniquement insaturé par hydroformylation en présence d'un système de
catalyseur composé d'un métal du Groupe VIII, d'un ligand de phosphite organique et
d'un solvant de réaction, dans lequel le ligand de phosphite organique est un ligand
contenant un phosphore présentant la structure (PR<sub>2</sub>)<sub>n</sub>R', où n est 2, R et R' sont des
résidus organiques qui peuvent être identiques ou différents et où R ou R' contient au
moins un groupe aliphatique C<sub>9</sub> à C<sub>40</sub> positionné en tant qu'extrémité éloignée de la
structure de ligand principale rendant le ligand lipophile, et dans lequel le solvant de
réaction est un mélange de deux phases d'un composé organique contenant de 5 à 20
atomes de carbone et d'un solvant polaire.</claim-text>
    </claim>
    <claim num="2">
      <claim-text>Procédé pour l'hydroformylation d'un composé éthyléniquement insaturé, dans
lequel les produits réactionnels incluant des produits réactionnels à haut point d'ébullition
sont facilement séparés du système de catalyseur, comprenant les étapes:
<claim-text><claim-text>a) de réaction dans un solvant de réaction pour former un mélange
réactionnel du composé éthyléniquement insaturé en présence d'un système de catalyseur
composé d'un métal du Groupe VIII et d'un ligand de phosphite organique contenant un
phosphore présentant la structure (PR<sub>2</sub>)<sub>n</sub>R', où n est 2, R et R' sont des résidus organiques
qui peuvent être identiques ou différents et où R ou R' contient au moins un groupe
aliphatique C<sub>9</sub> à C<sub>40</sub> positionné en tant qu'extrémité éloignée de la structure de ligand
principale rendant le ligand lipophile;</claim-text><claim-text>b) d'ajout d'un solvant non polaire au mélange réactionnel pour former deux
phases, l'une est une phase polaire formée de manière prédominante des produits
réactionnels et l'autre formée de manière prédominante du solvant non polaire et du
système de catalyseur de sorte que les produits réactionnels incluant les produits
réactionnels à haut point d'ébullition de l'hydroformylation restent dans la phase polaire
et que le système de catalyseur est séparé substantiellement dans la phase non polaire; et</claim-text><claim-text>c) de séparation des deux phases et d'isolement des produits réactionnels à
partir de la phase polaire et du catalyseur à partir de la phase non polaire.</claim-text></claim-text></claim-text>
    </claim>
    <claim num="3">
      <claim-text>Procédé suivant la revendication 1 ou 2, dans lequel le solvant de réaction est le
composé éthyléniquement insaturé.</claim-text>
    </claim>
    <claim num="4">
      <claim-text>Procédé suivant la revendication 2, dans lequel les composés volatils sont retirés
du mélange réactionnel de l'étape (a) avant l'ajout du solvant non polaire de l'étape (b).</claim-text>
    </claim>
    <claim num="5">
      <claim-text>Procédé suivant la revendication 2, dans lequel les étapes (a) et (b) sont combinées
et l'hydroformylation est réalisée dans un solvant de réaction à deux phases.</claim-text>
    </claim>
    <claim num="6">
      <claim-text>Procédé suivant la revendication 2, dans lequel le catalyseur récupéré est retourné
vers l'étape (a) et les étapes sont répétées. </claim-text>
    </claim>
    <claim num="7">
      <claim-text>Procédé suivant la revendication 1 ou 2, dans lequel le solvant non polaire est
choisi dans le groupe constitué de solvants hydrocarbures C<sub>5</sub> à C<sub>20</sub>.</claim-text>
    </claim>
    <claim num="8">
      <claim-text>Procédé suivant l'une quelconque des revendications 1 et 2, dans lequel le
composé éthyléniquement insaturé est choisi dans le groupe constitué de l'acide 3-penténoïque,
d'esters d'alkyle C<sub>1</sub> à C<sub>6</sub> de l'acide 3-penténoïque, du 3-pentènenitrile et du
4-pentènenitrile.</claim-text>
    </claim>
    <claim num="9">
      <claim-text>Procédé suivant la revendication 1 ou 2, dans lequel le ligand organique est choisi
parmi les structures A et B:
<img id="img-00310001" orientation="unknown" wi="130" img-format="tif" img-content="cf" file="00310001.tif" inline="no" he="62"/>
où les structures A sont pour les ligands I à III et les structures B sont pour les ligands IV
à IX, ligand I, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est H; ligand II, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est
CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; ligand III, R<sub>1</sub> et R<sub>2</sub> sont (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; ligand IV, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> est
O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>3</sub> est H; ligand V, R<sub>1</sub> est (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> et R<sub>2</sub> et R<sub>3</sub> sont H; ligand VI, R<sub>1</sub> est
CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> et R<sub>2</sub> et R<sub>3</sub> sont H; ligand VII, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est H et R<sub>3</sub>
est OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; ligand VIII, R<sub>1</sub> est CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) et R<sub>2</sub> et R<sub>3</sub>
sont H; et ligand IX est CH<sub>2</sub>CH(R<sub>4</sub>)(R<sub>5</sub>) et R<sub>4</sub> et R<sub>5</sub> sont des hydrocarbures identiques ou
différents contenant de 6 à 30 atomes de carbone.</claim-text>
    </claim>
    <claim num="10">
      <claim-text>Procédé d'hydroformylation amélioré pour la préparation d'un aldéhyde linéaire à
partir d'un mélange réactionnel contenant un composé éthyléniquement insaturé et un
système de catalyseur composé d'un métal du Groupe VIII et d'un ligand de phosphite
organique bidenté contenant deux atomes de phosphore trivalents, dans lequel le composé
éthyléniquement insaturé agit également comme un solvant de réaction, l'amélioration
comprenant: la formation du système de catalyseur à partir d'un ligand contenant au
moins un groupe aliphatique C<sub>9</sub> à C<sub>40</sub> positionné sur le squelette ou des structures de
cycles de bras latéral du ligand et, à la suite de l'hydroformylation du composé
éthyléniquement insaturé, l'ajout au mélange réactionnel d'un mélange de solvants à deux
phases constitué d'un composant polaire et d'un composant non polaire de sorte que les
produits réactionnels de l'hydroformylation sont extraits dans la phase polaire du mélange
de solvants et que le système de catalyseur reste substantiellement dans la phase non
polaire du mélange de solvants. </claim-text>
    </claim>
    <claim num="11">
      <claim-text>Procédé suivant la revendication 10, dans lequel le solvant non polaire est choisi
dans le groupe de solvants hydrocarbures C<sub>5</sub> à C<sub>20</sub>.</claim-text>
    </claim>
    <claim num="12">
      <claim-text>Procédé suivant la revendication 10, dans lequel le composé éthyléniquement
insaturé est choisi dans le groupe constitué de l'acide 3-penténoïque, d'esters d'alkyle C1
à C6 de l'acide 3-penténoïque, du 3-pentènenitrile et du 4-pentènenitrile.</claim-text>
    </claim>
    <claim num="13">
      <claim-text>Procédé suivant la revendication 10, dans lequel le ligand organique est choisi
parmi les structures A et B:
<img id="img-00320001" orientation="unknown" wi="134" img-format="tif" img-content="cf" file="00320001.tif" inline="no" he="61"/>
où les structures A sont pour les ligands I à III et les structures B sont pour les ligands IV
à IX, ligand I, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est H; ligand II, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est
CO(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>; ligand III, R<sub>1</sub> et R<sub>2</sub> sont (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; ligand IV, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>, R<sub>2</sub> est
O(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>3</sub> est H; ligand V, R<sub>1</sub> est (CH<sub>2</sub>)<sub>17</sub>CH<sub>3</sub> et R<sub>2</sub> et R<sub>3</sub> sont H; ligand VI, R<sub>1</sub> est
CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub> et R<sub>2</sub> et R<sub>3</sub> sont H; ligand VII, R<sub>1</sub> est (CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub> et R<sub>2</sub> est H et R<sub>3</sub>
est OSi(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; ligand VIII, R<sub>1</sub> est CH<sub>2</sub>CH((CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub>)((CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>) et R<sub>2</sub> et R<sub>3</sub>
sont H; et ligand IX est CH<sub>2</sub>CH(R<sub>4</sub>)(R<sub>5</sub>) et R<sub>4</sub> et R<sub>5</sub> sont des hydrocarbures identiques ou
différents contenant de 6 à 30 atomes de carbone.</claim-text>
    </claim>
    <claim num="14">
      <claim-text>Procédé suivant la revendication 1, 2 ou 10, dans lequel le métal du Groupe VIII
est le rhodium.</claim-text>
    </claim>
  </claims>
  <copyright>User acknowledges that the Information Retrieval Facility (IRF) and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws. User acquires no ownership rights to this xml including but not limited to its format. User hereby accepts the terms and conditions of the Licence Agreement set forth at http://www.ir-facility.org/legal/marec/data_licence</copyright>
</patent-document>
